[go: up one dir, main page]

NO20060386L - Isetionatsalt av en selektiv CDK4-inhibitor - Google Patents

Isetionatsalt av en selektiv CDK4-inhibitor

Info

Publication number
NO20060386L
NO20060386L NO20060386A NO20060386A NO20060386L NO 20060386 L NO20060386 L NO 20060386L NO 20060386 A NO20060386 A NO 20060386A NO 20060386 A NO20060386 A NO 20060386A NO 20060386 L NO20060386 L NO 20060386L
Authority
NO
Norway
Prior art keywords
cdk4 inhibitor
selective cdk4
isetionate
salt
isetionate salt
Prior art date
Application number
NO20060386A
Other languages
English (en)
Other versions
NO335100B1 (no
Inventor
Vladimir Genukh Beylin
Peter Laurence Toogood
Anthony Clyde Blackburn
David Thomas Erdman
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20060386L publication Critical patent/NO20060386L/no
Publication of NO335100B1 publication Critical patent/NO335100B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Beskrevet er polymorfer av isetionatsaltet av 6-acetyl-8-cyklopentyl-5metyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-on, som er en selektiv cyklin-avhengig kinase 4- (CDK4) inhibitor anvendelig for behandling av inflammasjon og celle-proliferative sykdommer så som kreft og restenose.
NO20060386A 2003-07-11 2006-01-24 Isetionatsalt, fremgangsmåte for fremstilling av slike, farmasøytisk doseform omfattende slike samt slike forbindelser for behandling av sykdom NO335100B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48635103P 2003-07-11 2003-07-11
PCT/IB2004/002152 WO2005005426A1 (en) 2003-07-11 2004-06-28 Isethionate salt of a selective cdk4 inhibitor

Publications (2)

Publication Number Publication Date
NO20060386L true NO20060386L (no) 2006-04-05
NO335100B1 NO335100B1 (no) 2014-09-15

Family

ID=34062121

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060386A NO335100B1 (no) 2003-07-11 2006-01-24 Isetionatsalt, fremgangsmåte for fremstilling av slike, farmasøytisk doseform omfattende slike samt slike forbindelser for behandling av sykdom

Country Status (31)

Country Link
US (2) US7345171B2 (no)
EP (1) EP1648889B1 (no)
JP (1) JP4053073B2 (no)
KR (1) KR100816945B1 (no)
CN (1) CN1835951B (no)
AR (1) AR045898A1 (no)
AT (1) ATE412650T1 (no)
AU (1) AU2004255934B2 (no)
BR (1) BRPI0412516A (no)
CA (1) CA2532049C (no)
CL (1) CL2004001701A1 (no)
CY (1) CY1108589T1 (no)
DE (1) DE602004017474D1 (no)
DK (1) DK1648889T3 (no)
ES (1) ES2313016T3 (no)
GT (1) GT200400130A (no)
IL (1) IL173034A (no)
MX (1) MXPA06000484A (no)
NL (1) NL1026624C2 (no)
NO (1) NO335100B1 (no)
NZ (1) NZ544609A (no)
PA (1) PA8606501A1 (no)
PE (1) PE20050700A1 (no)
PL (1) PL1648889T3 (no)
PT (1) PT1648889E (no)
RU (1) RU2317296C2 (no)
SI (1) SI1648889T1 (no)
TW (1) TWI288750B (no)
UY (1) UY28404A1 (no)
WO (1) WO2005005426A1 (no)
ZA (1) ZA200600230B (no)

Families Citing this family (126)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20063909B (en) 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
EP1740184A1 (en) * 2004-03-30 2007-01-10 Pfizer Products Incorporated Combinations of signal transduction inhibitors
KR20140105621A (ko) * 2005-10-07 2014-09-01 엑셀리시스, 인코포레이티드 ＰＩ３Ｋα의 피리도피리미디논 억제제
US8247408B2 (en) * 2005-10-07 2012-08-21 Exelixis, Inc. Pyridopyrimidinone inhibitors of PI3Kα for the treatment of cancer
EP2069344A2 (en) * 2006-09-08 2009-06-17 Pfizer Products Inc. Synthesis of 2-(pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones
MX2009002927A (es) 2006-09-15 2009-03-31 Pfizer Prod Inc Compuestos de pirido (2,3-d)pirimidinona y su uso como inhibidores de la enzima fosfoinositido 3.
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
AU2007333791A1 (en) * 2006-12-14 2008-06-26 Panacea Pharmaceuticals, Inc. Methods of neuroprotection by cyclin-dependent kinase inhibition
WO2009061345A2 (en) * 2007-11-07 2009-05-14 Cornell Research Foundation, Inc. Targeting cdk4 and cdk6 in cancer therapy
MX2010006457A (es) * 2007-12-19 2010-07-05 Amgen Inc Compuestos fusionados de piridina, pirimidina y triazina como inhibidores de ciclo celular.
CA2719538C (en) * 2008-04-07 2014-03-18 Amgen Inc. Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
EP2341906A4 (en) * 2008-10-01 2012-06-13 Univ North Carolina HEMATOPOIETIC PROTECTION AGAINST IONIZATION RADIATION USING SELF-ACTIVE CYCLINE-DEPENDENT KINASE-4/6-HEMMER
AU2009298367A1 (en) * 2008-10-01 2010-04-08 The University Of North Carolina At Chapel Hill Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors
JO2885B1 (en) * 2008-12-22 2015-03-15 ايلي ليلي اند كومباني Protein kinase inhibitors
EA022924B1 (ru) 2009-04-03 2016-03-31 Ф.Хоффманн-Ля Рош Аг ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ
EP3406260B1 (en) 2009-05-13 2020-09-23 The University of North Carolina at Chapel Hill Cyclin dependent kinase inhibitors and methods of use
MA33975B1 (fr) 2009-11-06 2013-02-01 Plexxikon Inc Composés et méthodes de modulation des kinases et leurs indications d'emploi
PH12012501361A1 (en) 2009-12-31 2012-10-22 Centro Nac De Investigaciones Oncologicas Cnio Tricyclic compounds for use as kinase inhibitors
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
US8691830B2 (en) 2010-10-25 2014-04-08 G1 Therapeutics, Inc. CDK inhibitors
WO2012068381A2 (en) * 2010-11-17 2012-05-24 The University Of North Carolina At Chapel Hill Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
WO2012098387A1 (en) 2011-01-18 2012-07-26 Centro Nacional De Investigaciones Oncológicas (Cnio) 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
JP5941069B2 (ja) 2011-02-07 2016-06-29 プレキシコン インコーポレーテッドＰｌｅｘｘｉｋｏｎ Ｉｎｃ． キナーゼ調節のための化合物および方法、ならびにそれに対する適応症
DK2688887T3 (en) 2011-03-23 2015-06-29 Amgen Inc DEHYDRATED tricyclic DUALINHIBITORER OF CDK 4/6 AND FLT3
EP2721686B1 (en) * 2011-06-17 2018-11-28 NantEnergy, Inc. Ionic liquid containing sulfonate ions
EP2831080B1 (en) 2012-03-29 2017-03-15 Francis Xavier Tavares Lactam kinase inhibitors
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
HUE040434T2 (hu) * 2013-02-21 2019-03-28 Pfizer Szelektív CDK4/6 inhibitor szilárd alakjai
EP2968291B1 (en) 2013-03-15 2025-04-16 Pharmacosmos Holding A/S Hspc-sparing treatments for rb-positive abnormal cellular proliferation
EP2967050A4 (en) 2013-03-15 2016-09-28 G1 Therapeutics Inc HIGH-ACTIVE ANTINEOPLASTIC AND ANTIPROLIFERATIVE AGENTS
AU2014235462C1 (en) * 2013-03-15 2018-11-01 Concert Pharmaceuticals, Inc. Deuterated palbociclib
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
US9717735B2 (en) 2014-04-17 2017-08-01 G1 Therapeutics, Inc. Tricyclic lactams for use in HSPC-sparing treatments for RB-positive abnormal cellular proliferation
WO2016015597A1 (en) * 2014-07-26 2016-02-04 Sunshine Lake Pharma Co., Ltd. Compounds as cdk small-molecule inhibitors and uses thereof
WO2016016769A1 (en) * 2014-07-31 2016-02-04 Sun Pharmaceutical Industries Limited A process for the preparation of palbociclib
EP3180007A1 (en) * 2014-08-14 2017-06-21 Sun Pharmaceutical Industries Ltd Crystalline forms of palbociclib
WO2016040848A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Treatment of rb-negative tumors using topoisomerase inhibitors in combination with cyclin dependent kinase 4/6 inhibitors
WO2016040858A1 (en) 2014-09-12 2016-03-17 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
CN105622638B (zh) * 2014-10-29 2018-10-02 广州必贝特医药技术有限公司 嘧啶或吡啶并吡啶酮类化合物及其制备方法和应用
WO2016066420A1 (en) * 2014-10-29 2016-05-06 Sandoz Ag Crystalline forms of palbociclib monohydrochloride
CN105616418A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂的药物制剂及其制备方法
CN105616419A (zh) * 2014-11-07 2016-06-01 江苏豪森药业集团有限公司 含有细胞周期蛋白抑制剂固体分散体的药物组合物及其制备方法
SI3218005T1 (sl) 2014-11-12 2023-06-30 Seagen Inc. Z glikanom delujoče spojine, in postopki uporabe
WO2016090257A1 (en) * 2014-12-05 2016-06-09 Crystal Pharmatech Inc. Salts and crystalline forms of 6-acetyl-8-cyclopentyl-5-methyl-2((5-(piperazin-1-yl)pyridin-2-yl)amino)pyrido[2,3-d] pyrimidin-7(8h)-one (palbociclib)
WO2016092442A1 (en) * 2014-12-08 2016-06-16 Sun Pharmaceutical Industries Limited Processes for the preparation of crystalline forms of palbociclib acetate
CN105732615B (zh) * 2014-12-31 2018-05-01 山东轩竹医药科技有限公司 Cdk激酶抑制剂
HUE047626T2 (hu) * 2015-02-03 2020-05-28 Jiangsu Hengrui Medicine Co Ciklin-függõ, fehérje kináz inhibitor hidroxietil-szulfonátja, annak kristályos formája és elõállítására szolgáló eljárás
CZ201589A3 (cs) 2015-02-11 2016-08-24 Zentiva, K.S. Pevné formy soli Palbociclibu
AR104068A1 (es) 2015-03-26 2017-06-21 Hoffmann La Roche Combinaciones de un compuesto inhibidor de fosfoinosítido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cáncer
EP3078663A1 (en) 2015-04-09 2016-10-12 Sandoz Ag Modified particles of palbociclib
WO2016156070A1 (en) 2015-04-02 2016-10-06 Sandoz Ag Modified particles of palbociclib
CN104910149A (zh) * 2015-04-28 2015-09-16 上海百奇医药科技有限公司 一种Palbociclib制备方法
CN106117199A (zh) * 2015-05-04 2016-11-16 江苏恒瑞医药股份有限公司 一种细胞周期蛋白依赖性激酶抑制剂的二羟乙基磺酸盐、其结晶形式及其制备方法
HRP20211360T1 (hr) * 2015-05-29 2021-11-26 Teijin Pharma Limited Derivat pirido[3,4-d]pirimidina i njegova farmaceutski prihvatljiva sol
KR102068423B1 (ko) * 2015-06-04 2020-01-20 화이자 인코포레이티드 팔보시클립의 고체 투여 형태
CN106317053A (zh) * 2015-06-29 2017-01-11 北大方正集团有限公司 一种帕博昔布晶型a的制备方法
EP3543235A1 (en) 2015-08-05 2019-09-25 ratiopharm GmbH Crystalline form and acetic acid adduct of palbociclib
CN105085517B (zh) * 2015-08-06 2016-11-23 天津华洛康生物科技有限公司 一种结晶型帕博西尼游离碱水合物及其制备方法
CN106474129A (zh) * 2015-09-01 2017-03-08 上海方楠生物科技有限公司 一种帕博西林或其药学上可接受的盐与药用辅料的组合物及其制备方法
HU230962B1 (hu) 2015-10-28 2019-06-28 Egis Gyógyszergyár Zrt. Palbociclib sók
CA3002097A1 (en) 2015-11-12 2017-05-18 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN105418603A (zh) * 2015-11-17 2016-03-23 重庆莱美药业股份有限公司 一种高纯度帕布昔利布及其反应中间体的制备方法
CN106800554A (zh) * 2015-11-26 2017-06-06 上海科胜药物研发有限公司 一种帕博西尼二盐酸盐的晶型及其制备方法
CN106800553A (zh) * 2015-11-26 2017-06-06 上海科胜药物研发有限公司 一种帕博西尼二羟乙基磺酸盐的晶型
CN105541832A (zh) * 2015-12-15 2016-05-04 南京艾德凯腾生物医药有限责任公司 一种羟乙基磺酸盐帕布昔利布的制备方法
WO2017130219A1 (en) 2016-01-25 2017-08-03 Mylan Laboratories Limited Amorphous solid dispersion of palbociclib
WO2017145054A1 (en) 2016-02-24 2017-08-31 Lupin Limited Modified particles of crystalline palbociclib free base and process for the preparation thereof
CN107137409A (zh) * 2016-03-01 2017-09-08 江苏恒瑞医药股份有限公司 一种cdk4/6抑制剂与雌激素受体拮抗剂联合在制备治疗乳腺癌的药物中的用途
CN107137408A (zh) * 2016-03-01 2017-09-08 江苏恒瑞医药股份有限公司 一种cdk4/6抑制剂与芳香化酶抑制剂联合在制备治疗乳腺癌的药物中的用途
WO2017172734A1 (en) * 2016-03-29 2017-10-05 Mayo Foundation For Medical Education And Research Treating cancer metastasis
US10449195B2 (en) 2016-03-29 2019-10-22 Shenzhen Pharmacin Co., Ltd. Pharmaceutical formulation of palbociclib and a preparation method thereof
WO2018001270A1 (en) * 2016-06-30 2018-01-04 Noratech Pharmaceuticals, Inc. Palbociclib prodrugs and composition thereof
WO2018005863A1 (en) 2016-07-01 2018-01-04 G1 Therapeutics, Inc. Pyrimidine-based compounds for the treatment of cancer
EP3481825A1 (en) * 2016-07-07 2019-05-15 Plantex Ltd. Solid state forms of palbociclib dimesylate
UA124804C2 (uk) 2016-08-15 2021-11-24 Пфайзер Інк. Піридопіримідинонові інгібітори cdk2/4/6
WO2018065999A1 (en) 2016-10-07 2018-04-12 Mylan Laboratories Limited Novel polymorph of an intermediate for palbociclib synthesis
WO2018073574A1 (en) 2016-10-20 2018-04-26 Cipla Limited Polymorphic forms of palbociclib
BR112019005526A2 (pt) 2016-10-20 2019-06-18 Pfizer agentes antiproliferativos para tratamento de pah
CA3043681A1 (en) 2016-11-16 2018-05-24 Pfizer Inc. Combination of an egfr t790m inhibitor and a cdk inhibitor for the treatment of non-small cell lung cancer
EP3541847A4 (en) 2016-11-17 2020-07-08 Seattle Genetics, Inc. COMPOUNDS INTERACTING WITH GLYCANE AND METHODS OF USE
CA3041854C (en) * 2016-11-28 2025-05-13 Teijin Pharma Limited PYRIDO DERIVATIVE CRYSTAL [3,4-D]PYRIMIDINE OR ITS SOLVA
AU2018205262A1 (en) 2017-01-06 2019-07-11 G1 Therapeutics, Inc. Combination therapy for the treatment of cancer
EP3589319A4 (en) 2017-03-03 2021-07-14 Seagen Inc. COMPOUNDS INTERACTING WITH GLYCAN AND METHODS OF USE
WO2018191950A1 (en) * 2017-04-21 2018-10-25 Alnova Pharmaceuticals, Ltd. Palbociclib compositions and methods thereof
MX392531B (es) 2017-06-29 2025-03-24 G1 Therapeutics Inc Formas morficas de g1t38 y metodos de preparacion de las mismas.
WO2019020715A1 (en) 2017-07-28 2019-01-31 Synthon B.V. PHARMACEUTICAL COMPOSITION COMPRISING PALBOCICLIB
TW201940166A (zh) * 2018-01-29 2019-10-16 美商貝達醫藥公司 作為cdk4及cdk6抑制劑之2h-吲唑衍生物及其治療用途
KR102765922B1 (ko) 2018-02-06 2025-02-11 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 선택적인 에스트로겐 수용체 분해제로서의 치환된 벤조티오펜 유사체
WO2019166928A1 (en) 2018-02-27 2019-09-06 Pfizer Inc. Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor
EP3793609B1 (en) 2018-05-14 2023-12-13 Pfizer Inc. Oral solution formulation
CN117281814A (zh) 2018-07-23 2023-12-26 豪夫迈·罗氏有限公司 用pi3k抑制剂gdc-0077治疗癌症的方法
CN120817904A (zh) 2018-08-24 2025-10-21 法码科思莫斯有限公司 1,4-二氮杂螺[5.5]十一烷-3-酮改进的合成
JP6952747B2 (ja) 2018-09-18 2021-10-20 ファイザー・インク がん処置のためのＴＧＦβ阻害剤およびＣＤＫ阻害剤の組合せ
EP3863618A1 (en) 2018-10-08 2021-08-18 F. Hoffmann-La Roche AG Methods of treating cancer with pi3k alpha inhibitors and metformin
US11424484B2 (en) 2019-01-24 2022-08-23 Octet Scientific, Inc. Zinc battery electrolyte additive
WO2020157709A1 (en) 2019-02-01 2020-08-06 Pfizer Inc. Combination of a cdk inhibitor and a pim inhibitor
WO2020239558A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
WO2020240360A1 (en) 2019-05-24 2020-12-03 Pfizer Inc. Combination therapies using cdk inhibitors
CN112094272A (zh) 2019-06-18 2020-12-18 北京睿熙生物科技有限公司 Cdk激酶抑制剂
CN110143948B (zh) * 2019-06-21 2021-05-14 上海博悦生物科技有限公司 Cdk4/6抑制剂、其药物组合物、制备方法及应用
KR20220054347A (ko) 2019-08-26 2022-05-02 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 유도체로 유방암을 치료하는 방법
JP2023504436A (ja) 2019-12-03 2023-02-03 ジェネンテック， インコーポレイテッド 乳がんの治療のための併用療法
US20230117684A1 (en) 2020-03-05 2023-04-20 Pfizer Inc. Combination of an anaplastic lymphoma kinase inhibitor and a cyclin dependent kinase inhibitor
US10988479B1 (en) 2020-06-15 2021-04-27 G1 Therapeutics, Inc. Morphic forms of trilaciclib and methods of manufacture thereof
EP4181920B1 (en) 2020-07-15 2025-09-10 Pfizer Inc. Kat6 inhibitor and combinations for breast cancer treatment
JP2022020583A (ja) 2020-07-20 2022-02-01 ファイザー・インク 併用療法
CN114246841B (zh) * 2020-09-24 2024-02-02 南京济群医药科技股份有限公司 一种羟乙磺酸哌柏西利的组合物及药物
CN114306245A (zh) 2020-09-29 2022-04-12 深圳市药欣生物科技有限公司 无定形固体分散体的药物组合物及其制备方法
WO2022091001A1 (en) 2020-10-29 2022-05-05 Pfizer Ireland Pharmaceuticals Process for preparation of palbociclib
WO2022123419A1 (en) 2020-12-08 2022-06-16 Pfizer Inc. Treatment of luminal subtypes of hr-positive, her2-negative early breast cancer with palbociclib
CN113845520A (zh) * 2021-09-09 2021-12-28 安徽皓元药业有限公司 一种帕布昔利布乳清酸盐及其制备方法
KR20240118134A (ko) 2021-12-10 2024-08-02 일라이 릴리 앤드 캄파니 Cdk4 및 6 억제제로 이전에 치료된 환자에서의 호르몬 수용체-양성, 인간 표피 성장 인자 수용체 2-음성 진행성 또는 전이성 유방암의 치료를 위한 풀베스트란트와 조합된 cdk4 및 6 억제제
WO2023111810A1 (en) 2021-12-14 2023-06-22 Pfizer Inc. Combination therapies and uses for treating cancer
WO2023114264A1 (en) 2021-12-15 2023-06-22 Eli Lilly And Company Combination for treatment of high-risk metastatic hormone-sensitive prostate cancer
CN114195784A (zh) * 2021-12-29 2022-03-18 斯坦德标准技术研究(湖北)有限公司 帕博西尼有关物质及其制备方法和应用
EP4302832A1 (en) 2022-07-07 2024-01-10 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing glucono delta lactone
EP4302755B1 (en) 2022-07-07 2025-08-20 Lotus Pharmaceutical Co., Ltd. Palbociclib formulation containing an amino acid
CN119604288A (zh) 2022-07-29 2025-03-11 辉瑞大药厂 用于治疗癌症的包含kat6抑制剂的给药方案
EP4580631A1 (en) 2022-08-31 2025-07-09 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
JP2024067010A (ja) 2022-11-02 2024-05-16 ペトラ・ファーマ・コーポレイション 疾患の治療用のホスホイノシチド３－キナーゼ（ｐｉ３ｋ）のアロステリッククロメノン阻害剤
WO2024133726A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2024132652A1 (en) 2022-12-22 2024-06-27 Synthon B.V. Pharmaceutical composition comprising palbociclib
WO2024201340A1 (en) 2023-03-30 2024-10-03 Pfizer Inc. Kat6a as a predictive biomarker for treatment of breast cancer with a cdk4 inhibitor and an antiestrogen and methods of treatment thereof
KR20250164842A (ko) 2023-03-30 2025-11-25 화이자 인코포레이티드 Kat6a 억제제에 의한 치료를 위한 예측 바이오마커로서의 kat6a 및 이의 치료 방법
WO2025122470A1 (en) 2023-12-04 2025-06-12 Genentech, Inc. Combination therapies for treatment of breast cancer
WO2025202854A1 (en) 2024-03-27 2025-10-02 Pfizer Inc. Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2146782T3 (es) * 1994-11-14 2000-08-16 Warner Lambert Co 6-aril-pirido(2,3-d)pirimidinas y naftiridinas para la inhibicion de la proliferacion celular inducida por la proteina tirosina quinasa.
DZ3308A1 (fr) * 2000-03-06 2001-09-27 Warner Lambert Co Inhibiteurs de tyrosine kinase a base de 5-alkylpyrido [2,3-d] pyrimidines
DE60106947T2 (de) * 2000-09-01 2005-11-10 Glaxo Group Ltd., Greenford Oxindolderivate
EP1463730B1 (en) * 2001-12-17 2006-04-19 SmithKline Beecham Corporation Pyrazolopyridazine derivatives
GEP20063909B (en) * 2002-01-22 2006-08-25 Warner Lambert Co 2-(PYRIDIN-2-YLAMINO)-PYRIDO[2,3d] PYRIMIDIN-7-ONES
WO2004032882A2 (en) * 2002-10-10 2004-04-22 Smithkline Beecham Corporation Chemical compounds
ES2315566T3 (es) * 2002-11-22 2009-04-01 Smithkline Beecham Corporation Tiazolidin-4-onas para inhibir proteinas hyak3.
JP2006516561A (ja) * 2003-01-17 2006-07-06 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 細胞増殖の阻害剤としての２−アミノピリジン置換ヘテロ環類
US7507834B2 (en) * 2003-02-27 2009-03-24 Smithkline Beechan Corporation Substituted anilinopyrazoles

Also Published As

Publication number Publication date
RU2006101052A (ru) 2006-07-27
CY1108589T1 (el) 2014-04-09
AU2004255934B2 (en) 2010-02-25
WO2005005426A1 (en) 2005-01-20
NL1026624C2 (nl) 2005-07-20
JP4053073B2 (ja) 2008-02-27
TW200516079A (en) 2005-05-16
GT200400130A (es) 2005-07-14
HK1091205A1 (zh) 2007-01-12
CA2532049A1 (en) 2005-01-20
US7863278B2 (en) 2011-01-04
NO335100B1 (no) 2014-09-15
DK1648889T3 (da) 2009-01-05
MXPA06000484A (es) 2006-04-05
CL2004001701A1 (es) 2005-06-03
CA2532049C (en) 2010-07-20
PL1648889T3 (pl) 2009-03-31
NL1026624A1 (nl) 2005-01-12
AU2004255934A1 (en) 2005-01-20
CN1835951B (zh) 2010-06-02
PA8606501A1 (es) 2005-03-03
IL173034A0 (en) 2006-06-11
US20080021037A1 (en) 2008-01-24
ES2313016T3 (es) 2009-03-01
CN1835951A (zh) 2006-09-20
BRPI0412516A (pt) 2006-09-19
AR045898A1 (es) 2005-11-16
PT1648889E (pt) 2008-12-10
KR20060054300A (ko) 2006-05-22
UY28404A1 (es) 2005-02-28
ZA200600230B (en) 2007-04-25
US20050059670A1 (en) 2005-03-17
DE602004017474D1 (de) 2008-12-11
SI1648889T1 (sl) 2009-02-28
RU2317296C2 (ru) 2008-02-20
EP1648889A1 (en) 2006-04-26
JP2007530425A (ja) 2007-11-01
US7345171B2 (en) 2008-03-18
EP1648889B1 (en) 2008-10-29
KR100816945B1 (ko) 2008-03-25
ATE412650T1 (de) 2008-11-15
NZ544609A (en) 2008-07-31
PE20050700A1 (es) 2005-10-18
IL173034A (en) 2010-06-16
TWI288750B (en) 2007-10-21

Similar Documents

Publication Publication Date Title
NO20060386L (no) Isetionatsalt av en selektiv CDK4-inhibitor
UY27617A1 (es) 2 - (piridin -2 - ilamino) - pirido (2,3-d ) pirimidin -7 onas
DK1483265T3 (da) Purinderivater som kinaseinhibitorer
ATE362474T1 (de) Pyrazolo(1,5-a)pyrimidine als hemmstoffe cyclin- abhängiger kinasen
NO20053144L (no) Chk-, Pdk- og Akt-inhibitorpyrimidiner, deres fremstilling og anvendelse som famasoytiske midler.
PL378372A1 (pl) Tricykliczne związki jako inhibitory kinaz białkowych do wzmacniania skuteczności środków przeciwnowotworowych i radioterapii
NO20090631L (no) Morpholin pyrimidin derivativer anvendelige i behandlingen av proliferative lidelser
MXPA05013349A (es) Derivados de 2-amino-pirimidina como inhibidores de quinasa raf.
WO2004085418A3 (en) Xanthones, thioxanthones and acridinones as dna-pk inhibitors
SV2001000338A (es) Las 5- alquilpirido [2,3-d] pirimidinas son inhibidoras de la cinasas de tirosina y que dependen de la ciclina
NO20074964L (no) Pyrimidinderivater for behandling av hyperproliferative forstyrrelser
NO20060670L (no) N3-substituerte imidazopyridin C-kit inhibitorer
ATE433967T1 (de) 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
NO20063231L (no) Pyrido[2,3-D]pyrimidin-2,4-diaminer som PDE 2 inhibitorer
NO20080418L (no) Pyrido[2,3-D]pyrimidiriderivater, fremgangsmate for fremstilling derav og terapeutisk anvendelse av samme
DK1534707T3 (da) Substituerede 2,4-dihydropyrrolo[3,4-b]quinolin-9-on-derivater egnede som phosphodiesteraseinhibitorer
ATE335742T1 (de) Carbolinderivate als pdev inhibitoren
BRPI0312424A8 (pt) Derivados de pirazoloisoquinolinas para inibição de quinase indutora de nfkappab
NO20081818L (no) Arylsulfonylkromaner som 5-HT6-inhibitorer - indolylmaleimidderivater som protein kinaseinhibitorer
CU23294A3 (es) 2(piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
CR7392A (es) 2- (piridin-2-ilamino)-pirido[2,3-d]pirimidin-7-onas
DOP2004000947A (es) Sal de isetionato de un inhibidor selectivo de cdk4
NO20044323L (no) Benzensulfonatsalt av et morfolinureaderivat for anvendelse som en CCR-3 antagonist for behandling av inflammatoriske tilstander
UY26606A1 (es) Las 5-alquilpirido (2,3-d) pirimidinas son inhibidoras de las cinasas de tirosina, y que dependen de la ciclina.
CU23566B7 (es) Derivados de pirrolo [3,4-c]pirazol activos como inhibidores de quinasa

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: WARNER-LAMBERT COMPANY LLC, US

CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 488, 0213 OSLO, NORGE